Shanghai Xiao Fang Pharmaceutical Co.,Ltd. (SHA:603207)
China · Delayed Price · Currency is CNY 24.46
+0.32 (1.33%)
At close: Sep 30, 2026
SHA:603207 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 3,930 | 4,595 | 4,494 | - | - | - | |
Market Cap Growth | -27.00% | 2.24% | - | - | - | - |
Enterprise Value | 3,265 | 3,862 | 3,642 | - | - | - |
Last Close Price | 24.46 | 28.17 | 25.77 | - | - | - |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 20.39 | 22.15 | 21.90 | - | - | - |
PS Ratio | 7.31 | 8.75 | 9.47 | - | - | - |
PB Ratio | 3.44 | 4.21 | 3.64 | - | - | - |
P/TBV Ratio | 3.51 | 4.30 | 3.72 | - | - | - |
P/FCF Ratio | 47.14 | 43.13 | 35.04 | - | - | - |
P/OCF Ratio | 23.36 | 28.58 | 21.18 | - | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 6.08 | 7.35 | 7.68 | - | - | - |
EV/EBITDA Ratio | 14.59 | 16.08 | 15.44 | - | - | - |
EV/EBIT Ratio | 14.85 | 16.21 | 15.60 | - | - | - |
EV/FCF Ratio | 39.16 | 36.24 | 28.40 | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
Debt / EBITDA Ratio | 0.04 | 0.01 | 0.01 | 0.00 | 0.00 | 0.01 |
Debt / FCF Ratio | 0.11 | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 |
Net Debt / Equity Ratio | -0.58 | -0.59 | -0.71 | -0.50 | -0.45 | -0.90 |
Net Debt / EBITDA Ratio | -2.98 | -2.69 | -3.73 | -1.23 | -0.84 | -1.41 |
Net Debt / FCF Ratio | -7.98 | -6.05 | -6.87 | -2.39 | -2.22 | -1.24 |
Asset Turnover | 0.42 | 0.40 | 0.45 | 0.80 | 1.08 | 1.20 |
Inventory Turnover | 4.01 | 3.22 | 3.43 | 3.05 | 3.39 | 3.15 |
Quick Ratio | 5.08 | 5.29 | 5.80 | 2.84 | 2.80 | 1.70 |
Current Ratio | 5.55 | 5.88 | 6.14 | 3.42 | 3.64 | 2.10 |
Return on Equity (ROE) | 17.02% | 17.83% | 22.63% | 42.77% | 58.25% | 56.79% |
Return on Assets (ROA) | 10.73% | 11.27% | 13.80% | 24.50% | 28.82% | 26.63% |
Return on Invested Capital (ROIC) | 38.23% | 51.17% | 62.01% | 79.69% | 146.90% | 186.30% |
Return on Capital Employed (ROCE) | 19.20% | 21.80% | 18.90% | 39.70% | 52.50% | 62.00% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 4.89% | 4.52% | 4.57% | - | - | - |
FCF Yield | 2.12% | 2.32% | 2.85% | - | - | - |
Dividend Yield | 4.37% | 3.80% | 5.82% | - | - | - |
Payout Ratio | 68.73% | 170.24% | - | - | 63.59% | 66.97% |
Buyback Yield / Dilution | -3.59% | -19.89% | -12.01% | 0.17% | 0.22% | - |
Total Shareholder Return | 0.78% | -16.09% | -6.19% | 0.17% | 0.22% | - |